Results 21 to 30 of about 614,006 (307)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells

Frontiers in Immunology, 2023
Chimeric antigen receptors (CARs) in the canonical “second generation” format provide two signals for inducing T cell effector functions; the primary “signal-1” is provided through the TCR CD3ζ chain and the “signal-2” through a linked costimulatory ...
Simone Thomas, Simone Thomas, Hinrich Abken, Hinrich Abken   +3 more
doaj   +1 more source

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing [PDF]

, 2019
BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date.
Andersch, Lena, Eggert, Angelika, Flemmig, Carina, Grunewald, Laura, Henssen, Anton, Jensen, Michael C., Joussen, Antonia, Klaus, Anika, Künkele, Annette, Radke, Josefine, Rossig, Claudia, Schulte, Johannes H., Schumann, Elisa, Schwiebert, Silke, Winkler, Annika, Zirngibl, Felix   +15 more
core   +2 more sources

TGF-β-responsive CAR-T cells promote anti-tumor immune function. [PDF]

, 2018
A chimeric antigen receptor (CAR) that responds to transforming growth factor beta (TGF-β) enables the engineering of T cells that convert this immunosuppressive cytokine into a potent T-cell stimulant.
Chang, ZeNan L, Chen, Yvonne Y, Hou, Andrew J, Lorenzini, Michael H, Zah, Eugenia   +4 more
core   +1 more source

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice

Nature Communications, 2023
Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all.
Xiaomeng Hu, Karl Manner, Rowena DeJesus, Kathy White, Corie Gattis, Priscilla Ngo, Christopher Bandoro, Eleonore Tham, Elaine Y. Chu, Chi Young, Frank Wells, Ronald Basco, Annabelle Friera, Divy Kangeyan, Pascal Beauchesne, William E. Dowdle, Tobias Deuse, Terry J. Fry, Aaron E. Foster, Sonja Schrepfer   +19 more
doaj   +1 more source

IL-7 and CCR2b Co-Expression-Mediated Enhanced CAR-T Survival and Infiltration in Solid Tumors

Frontiers in Oncology, 2021
Chimeric antigen receptor T (CAR-T) cells are not effective in solid tumor treatment due to reduced invasion and expansion, and short survival time. This study aimed to explore whether interleukin (IL)-7 and CCR2b expression could improve GD2-CAR-T cell ...
Guangchao Li, Guangchao Li, Qing Zhang, Zeping Han, Yangmin Zhu, Huijuan Shen, Zhi Liu, Zhao Zhou, Wen Ding, Siqi Han, Jinhua He, Zhao Yin, Jie Zhou, Ruiming Ou, Min Luo, Min Luo, Shuang Liu   +16 more
doaj   +1 more source

Myeloid conditioning with c-kit-targeted CAR-T cells enables donor stem cell engraftment [PDF]

, 2018
We report a novel approach to bone marrow (BM) conditioning using c-kit-targeted chimeric antigen receptor T (c-kit CAR-T) cells in mice. Previous reports using anti-c-kit or anti-CD45 antibody linked to a toxin such as saporin have been promising.
Arai, Yasuyuki, Black, Mary A, Choi, Uimook, Corsino, Cristina I, Dinauer, Mary C, Feldman, Steven A, Koontz, Sherry M, Malech, Harry L, Sweeney, Colin L, Tajima, Masaki   +9 more
core   +2 more sources

Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia [PDF]

, 2016
Background Elderly patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have poor prognosis. Autologous CD19 chimeric antigen receptor-modified T (CAR-T) cells have potentials to cure patients with B cell ALL; however, safety and ...
Bingxia Li, Bo Cai, Bo Yao, Changlin Yu, Hanren Dai, Hongli Zuo, Huisheng Ai, Jianhui Qiao, Jun Yang, Kaixun Hu, Mei Guo, Mingxing Feng, Qiyun Sun, Tieqiang Liu, Weidong Han, Yajing Huang, Yajing Zhang, Yao Wang, Yelei Guo, Yi Wang, Yujing Sun, Zechuan Zhang, Zheng Dong, Zhiqing Liu   +23 more
core   +5 more sources

Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells in vitro and in vivo

Frontiers in Bioscience-Landmark, 2020
Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated clinical success in treatment of B-cell hematologic cancers. In this study, we compared human Transferrin epitope tagged CAR-T cells with non-tagged CAR-T cells for cytotoxicity, IFN ...
Michael Valentine, Le Li, Hua Zhou, Shirley Xu, Jinying Sun, Chengjing Liu, Hizkia Harto, Robert Berahovich, Vita Golubovskaya, Lijun Wu   +9 more
doaj   +1 more source

Nanobody based dual specific CARs [PDF]

, 2018
Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich, Bonte, Sarah, De Munter, Stijn, Goetgeluk, Glenn, Ingels, Joline, Kerre, Tessa, Pille, Melissa, Vandekerckhove, Bart, Weening, Karin   +8 more
core   +2 more sources

CAR-T Cell Therapy for Lymphoma [PDF]

Annual Review of Medicine, 2016
Lymphomas arise from clonal expansions of B, T, or NK cells at different stages of differentiation. Because they occur in the immunocyte-rich lymphoid tissues, they are easily accessible to antibodies and cell-based immunotherapy. Expressing chimeric antigen receptors (CARs) on T cells is a means of combining the antigen-binding site of a monoclonal ...
Carlos A, Ramos, Helen E, Heslop, Malcolm K, Brenner   +2 more
openaire   +2 more sources